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Abstract
Rationale Attention deficit hyperactivity disorder (ADHD)
and autism spectrum disorder (ASD) are often comorbid and
have both performance and brain dysfunctions during motor
response inhibition. Serotonin agonists modulate motor re-
sponse inhibition and have shown positive behavioural effects
in both disorders.
Aims We therefore used functional magnetic resonance imag-
ing (fMRI) to investigate the so far unknown shared and
disorder-specific inhibitory brain dysfunctions in these two
disorders, as well as the effects of a single dose of the selective
serotonin reuptake inhibitor fluoxetine.
Methods Age-matched boys with ADHD (18), ASD (19) and
healthy controls (25) were compared with fMRI during a stop
task measuring motor inhibition. Patients were scanned twice,
under either an acute dose of fluoxetine or placebo in a double-
blind, placebo-controlled randomised design. Repeated
measures analyses within patients assessed drug effects. To
test for potential normalisation effects of brain dysfunctions,
patients under each drug condition were compared to controls.
Results Under placebo, relative to controls, ASD boys
showed overactivation in left and right inferior frontal cortex
(IFC), while ADHD boys showed disorder-specific
underactivation in orbitofrontal cortex (OFC) and basal gan-
glia. Under fluoxetine, the prefrontal dysfunctions were no
longer observed, due to inverse effects of fluoxetine on these
activations: fluoxetine downregulated IFC and OFC activa-
tion in ASD but upregulated them in ADHD.
Conclusions The findings show that fluoxetine normalises
frontal lobe dysfunctions in both disorders via inverse effects,
downregulating abnormally increased frontal activation in
ASD and upregulating abnormally decreased frontal activa-
tion in ADHD, potentially reflecting inverse baseline seroto-
nin levels in both disorders.
Keywords ADHD . ASD .Motor response inhibition . Stop
task . fMRI . Serotonin . Fluoxetine
Introduction
Attention deficit hyperactivity disorder (ADHD) is a
neurodevelopmental disorder defined by age-inappropriate
levels of inattention, impulsivity and hyperactivity
(American Psychiatric Association 2000). Autism spectrum
disorder (ASD) is defined by impairments in communication,
social interaction and by restricted and repetitive behaviours
(American Psychiatric Association 2000). There is increasing
evidence for comorbidity between disorders (Rommelse et al.
2011; Simonoff et al. 2008; van der Meer et al. 2012) and
shared executive function deficits (Corbett et al. 2009; Geurts
et al. 2004), in particular in motor response inhibition
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(Alderson et al. 2007; Corbett et al. 2009; Lipsyzc and
Schachar 2010; Robinson et al. 2009), albeit less consistently
in ASD (Ozonoff and Strayer 1997; Raymaekers et al. 2007).
Furthermore, this has been associated with impulsiveness in
ADHD and motor stereotypies in ASD (Langen et al. 2011).
This overlap was highlighted by recent changes to the DSM-V
that allows co-diagnosis of ADHD and ASD (http://www.
dsm5.org/).
In ADHD, there is consistent evidence of underactivation
compared to controls in inferior/orbitofrontal frontal cortex
(IFC/OFC), supplementary motor area (SMA) and caudate/
thalamus during inhibition tasks (Cubillo et al. 2012; Rubia
2011; Rubia et al. 2014; Rubia et al. 1999; Rubia et al. 2005b;
Cortese et al. 2012; Hart et al. 2013). In children with ASD,
however, no study has investigated the neurofunctional un-
derpinnings of response inhibition. In adults with ASD, fMRI
studies report inconsistent findings of increased activation in
left IFC and decreased activation in right IFC and anterior
cingulate cortex (ACC) during the go/no-go task (Kana et al.
2007; Schmitz et al. 2006). Therefore, a key question is
whether the underlying neurobiology of shared cognitive phe-
notypes is shared or disorder-specific.
Serotonin (SE) is involved in impulsiveness and motor
inhibition (Robbins et al. 2010) and although selective sero-
tonin reuptake inhibitors (SSRIs) such as citalopram had no
effect on SSRT in healthy subjects (Chamberlain et al. 2006),
fMRI studies showed that SSRIs and acute tryptophan deple-
tion (ATD), which enhance/reduce SE levels, enhance/
decrease inhibitory IFC/OFC-striatal activation, respectively
(Lamar et al. 2012; Lamar et al. 2009; Rubia et al. 2005a).
Furthermore, there is evidence that 5-HT is involved in the
pathology of both ADHD and ASD. Thus, polymorphisms of
serotonergic genes have been associated with both ADHD and
ASD (Rommelse et al. 2010; Sinzig and Lehmkuhl 2007).
Moreover, biochemical serotonergic abnormalities have been
implicated in both ADHD (Oades 2007) and ASD (Zafeiriou
et al. 2009). Despite evidence for SE abnormalities in both
disorders, few studies have investigated the clinical efficacy of
SSRIs in ADHD and ASD. The SSRI fluoxetine, for example,
has been shown to improve inattentiveness and hyperactivity
in comorbid children with ADHD (Barrickman et al. 1991;
Gammon and Brown 1993; Quintana et al. 2007) and to
improve communication, social interaction and stereotyped
behaviours in children with ASD (DeLong et al. 2002;
DeLong et al. 1998; Hollander et al. 2005), albeit citalopram
was not effective (King et al. 2009).
Given the evidence for abnormalities in SE (Oades 2007;
Zafeiriou et al. 2009) and inhibition in both disorders
(Alderson et al. 2007; Corbett et al. 2009; Geurts et al. 2004;
Robinson et al. 2009; Rommelse et al. 2011) and serotonergic
mediation of inhibitory control (Anderson et al. 2008; Lamar
et al. 2012; Lamar et al. 2009; Robbins et al. 2010; Rubia et al.
2005a), an important question that may elucidate the potential
neurotransmitter underpinnings of these cognitive abnormali-
ties is whether SE modulates the inhibitory network in both
ADHD and ASD and whether this modulation differs between
disorders.
The aim of this fMRI study was therefore to investigate (1)
shared and disorder-specific brain dysfunctions in ADHD and
ASD boys during a tracking stop task and (2) shared and
disorder-specific neurofunctional effects of an acute dose of
fluoxetine on these inhibitory (dys)functions in both disorders.
It has been argued that inferior frontal activation during stop
task performance may be confounded by the attentional odd-
ball effect of the low frequency appearance of stop signals
(Hampshire et al. 2010; Pauls et al. 2012a). Given that in this
study we were particularly interested in the effects of fluoxe-
tine on inhibitory rather than on attention networks, in our
fMRI analysis we contrasted successful stop trials with failed
stop trials in order to control for the attentional oddball effect
of the low frequency appearance of the stop trials.
We hypothesised that, under placebo, ADHD boys com-
pared to controls would show decreased IFC and caudate
activation (Cortese et al. 2012; Cubillo et al. 2012; Cubillo
et al. 2014; Hart et al. 2013; Rubia 2011; Rubia et al. 1999;
Rubia et al. 2005b), whereas ASD boys would show increased
left frontal activation (Schmitz et al. 2006). We further
hypothesised that fluoxetine compared to placebo, given its
beneficial effects on symptoms, would normalise the abnor-
mal activations in each disorder, i.e. it would increase the
reduced fronto-striatal activation in ADHD, but reduce the
increased left frontal abnormalities in ASD.
Materials and methods
Participants
Sixty-two right-handed boys (Edinburgh Handedness
Inventory) (Oldfield 1971) (25 controls, 18 with ADHD and
19 with ASD) aged 10–17, IQ>70 (Wechsler Abbreviated
Scale of Intelligence-Revised (WASI-R) (Wechsler 1999) par-
ticipated in this study.
ADHD boys had a clinical diagnosis of non-comorbid
ADHD, inattentive/hyperactive-impulsive combined subtype,
as assessed by an experienced child psychiatrist using the
standardised Maudsley diagnostic interview that assesses
ADHD according to DSM-IV criteria (Goldberg and Murray
2006). They scored above clinical threshold for ADHD symp-
toms on the Strengths and Difficulties Questionnaire (SDQ)
(Goodman and Scott 1999) and the Conners’ Parent Rating
Scale-Revised (CPRS-R) (Conners et al. 1998). Four of the
ADHD boys were medication-naïve, three had ceased taking
methylphenidate for a year (1), or 3 months (2) and 11 re-
ceived chronic stimulants, but had a 48-h medication washout
prior to scanning. ADHD boys were excluded if they scored
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above 15 on the Social Communication Questionnaire (SCQ)
(Rutter et al. 2003).
ASD diagnosis was made using ICD-10 (World Health
Organisation (WHO) 1994) diagnostic criteria and confirmed
by the Autism Diagnostic Interview-Revised (ADI–R) (Lord
et al. 1994) and the Autism Diagnostic Observation Schedule
(ADOS) (Lord et al. 2000). All ASD subjects were medica-
tion-naïve apart from one patient, who took melatonin (but
underwent a 2-week medication washout). ASD exclusion
criteria included a score above 7 on the hyperactivity/
inattention subscale of the SDQ or a t score above 70 on the
DSM-IV subscale of the CPRS-R.
Exclusion criteria for all were comorbidity with other psy-
chiatric or neurological disorders and drug/alcohol dependen-
cy. Patients were recruited from local clinics and support
groups.
Patients were scanned twice in a double-blind, randomised,
placebo-controlled design, using a Latin square randomization
design for counter-balanced effects. Due to the half-life of
fluoxetine (1–3 days) and its metabolite norfluoxetine (5–
16 days) (Wong et al. 1995), each scan was 3–4 weeks apart.
To ensure that fluoxetine had reached its peak plasma levels,
after 5–8 h (Wong et al. 1995), patients were scanned 5 h after
administration. Liquid fluoxetine was titrated to age and
weight (see supplement). Placebo was equivalent amounts of
peppermint water with similar taste to fluoxetine.
Twenty-five healthy, handedness and age-matched boys
were recruited by advertisement and scored below clinical
thresholds on the SDQ, SCQ and CPRS.
Participants gave written informed consent/assent. The
study was approved by the local Ethics Committee.
Participants were paid £50 for each scan.
For recruitment, demographic and clinical details of partic-
ipants, see Table 1.
FMRI paradigm: stop task
Subjects practised the task once prior to each scan under
supervision of the researcher who made sure the participants
understood the task and performed accordingly (by inhibiting
more or less 50 % of trials). The 8 min 49 s minute visual
tracking stop task requires withholding of an already triggered
motor response to a go stimulus when it is followed unpre-
dictably by a stop signal (Cubillo et al. 2014; Rubia et al.
2011; Rubia et al. 2003; Rubia et al. 2005b; Rubia et al. 2007).
Subjects have to respond as quickly as possible to left or right
pointing “go” arrows (500 ms duration, 80 % of 294 trials)
with a left or right (thumb) button press, followed by a gap of
1100 to 1500 ms (which makes up a mean trial length of 1.8 s;
jittered between 1.6 and 2 s to optimise statistical efficiency).
In 20 % of trials (60), pseudo-randomly interspersed, and at
least 3 repetition times apart for adequate separation of the
hemodynamic response, go signals are followed (about
250 ms later) by arrows pointing upwards (300 ms duration)
(stop signals), and subjects have to inhibit their motor re-
sponse. A tracking algorithm changes the time interval be-
tween go and stop-signal onsets according to each subject’s
inhibitory performance, which is recalculated after each stop
signal based on the average percentage of inhibition over
previous stop trials to provide 50 % successful and 50 %
unsuccessful inhibition trials (Supplementary Figure S1).
Given that the contrast of stop-go trials is confounded by
the attentional oddball effect of the low frequency of stop trials
(20 %) relative to go trials (80 %), which also activates IFC
(Hampshire et al. 2010; Pauls et al. 2012b), for the fMRI
analysis, brain activation to the 50 % unsuccessful stop trials
was subtracted from the 50 % successful stop trials, control-
ling for the attentional oddball effect of the infrequent stop
signal appearance.
The dependent inhibition variable is the stop signal reaction
time (SSRT), calculated by subtracting the mean stop signal
delay (SSD: the average time between go and stop signal at
which the subject managed to inhibit to 50 % of trials) from
the mean reaction time (MRT) to go trials, i.e. MRT-SSD
(Logan et al. 1997). MRT, intrasubject standard deviation of
MRT, and omission error percentage are variables of the
executive process of the task.
Data analysis
Analysis of performance data
MANOVAs compared performance variables between con-
trols and the two patient groups under placebo and between
controls and the two patient groups under fluoxetine. Multiple
repeated-measures ANOVAs within the two patient groups
with group (ADHD, ASD) as independent factor and drug
condition (placebo/fluoxetine) as repeated measures were
conducted to test for group by medication interaction effects
on performance.
FMRI image acquisition
Gradient-echo echoplanar MR imaging (EPI) data were ac-
quired on a General Electric Signa 3T Horizon HDx system at
the Centre for Neuroimaging Sciences, Institute of Psychiatry,
King’s College London, UK. A semiautomated quality control
procedure ensured consistent image quality. A quadrature
birdcage headcoil was used for RF transmission and reception.
In each of 28 non-contiguous planes parallel to the anterior-
posterior commissure, 296 T2*-weighted MR images
depicting BOLD contrast covering the whole brain were ac-
quired with TE=30 ms, TR=1.8 s, flip angle=75°, in-plane
voxel-size=3 mm, slice thickness=5.5 mm and slice-skip=
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0.5 mm. Awhole-brain high-resolution structural scan (inver-
sion recovery gradient echo planar image) on which to super-
impose the individual activation maps, was also acquired in
the inter-commissural plane with TE=30 ms, TR=3 s, flip
angle=90°, 43 slices, slice thickness=3.0 mm, slice skip=
0.3 mm and in-plane voxel-size=1.875 mm.
All subjects performed three other fMRI tasks which are
not reported here.
FMRI image analysis
The XBAM software package was used (http://www.
brainmap.co.uk/) (Brammer et al. 1997) which makes no
normality assumptions (often violated in fMRI data), but
instead uses median statistics to control outlier effects and
permutation rather than normal theory-based inference
(Thirion et al. 2007).
Individual- and group-level analyses are described in fur-
ther detail elsewhere (Brammer et al. 1997; Cubillo et al.
2014; Rubia et al. 2003; Rubia et al. 2005b; Rubia et al.
2007) and in the supplementary material. Briefly, the fMRI
data were realigned to minimise motion-related artefacts and
smoothed using a Gaussian filter (FWHM 8.82 mm)
(Bullmore et al. 1999a). Further data analysis included slice
timing correction and the residual effects of motion were
regressed out from the time series (using the estimated motion
parameters) before fitting a general linear model. Time-series
analysis of individual subject activation was performed with a
wavelet-based resampling method previously described
(Bullmore et al. 2001). We convolved the task epoch of the
contrasts of interest (i.e. successful stop—implicit go trials;
failed stop trials—implicit go trials) and the higher level
contrast (successful stop-go trials minus unsuccessful stop-
go trials) with two Poisson model functions (delays of 4 and
8 s). Individual activation maps were recalculated by testing
the goodness-of-fit of this convolution with the BOLD time
series; the goodness-of-fit calculation used the ratio of the sum
of squares of deviations from the mean intensity value due to
the model (fitted time series) divided by the sum of squares
due to the residuals (original time series minus model time
series). This statistic, the sum of squares (SSQ) ratio, was used
in further analyses. Using rigid body and affine transforma-
tion, the individual maps were registered into Talairach stan-
dard space. A group brain activation map was then produced
for each medication condition and each experimental condi-
tion (see supplementary material).
ANCOVA between-group difference analyses
For between-group comparisons between controls and pa-
tients under either placebo or fluoxetine, one-way ANCOVA
analyses with group as factor and rotational and translation
movement in Euclidian 3-D space as covariate, were conduct-
ed using randomization-based tests for voxel or cluster-wise
differences as described in detail elsewhere (Bullmore et al.
2001; Bullmore et al. 1999b). For these between-group com-
parisons, less than one false activated cluster was expected at
p<0.05 for voxel and p<0.01 for cluster comparisons. Given
that right IFC was an a priori hypothesised region, we used a
more lenient cluster level threshold of p<0.05 and also
Table 1 Sample characteristics
for healthy control boys and
patients with ADHD and ASD
SDQ Strengths and Difficulties
Questionnaire, SCQ Social
Communication Questionnaire,











Age (years) 13.4 (2.4) 14.3 (1.8) 14.7 (2.0)
IQ 109 (13) 95 (11) 112 (15)
SDQ hyperactive-impulsive/inattentive subscale 1.8 (1.6) 9.2 (0.9) 4.5 (1.8)
SDQ—emotional distress subscale 0.5 (0.8) 3.6 (3.0) 4.2 (3.0)
SDQ—conduct subscale 0.3 (0.7) 5.0 (2.4) 2.1 (2.0)
SDQ—peer relations subscale .6 (1.1) 3.4 (2.5) 6.1 (2.4)
SDQ—prosocial behaviour subscale 9.1 (1.3) 6.7 (2.3) 5.1 (2.3)
SDQ—total scores 3.3 (2.9) 21.2 (4.9) 16.8 (5.7)
SCQ total 1.6 (2.7) 7.0 (3.4) 23.5 (5.5)
CPRS-R total T score 44 (3) 83 (7) 57 (8)
ADOS communication scores – – 2 (1)
ADOS social interaction scores – – 7 (4)
ADOS communication and social scores – – 9 (5)
ADOS stereotyped behaviour scores – – 1 (1)
ADI communication scores – – 14 (4)
ADI social Interaction scores – – 17 (5)
ADI stereotyped scores – – 6 (3)
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conducted a region of interest analysis using the IFC as a
mask. Then the standardised BOLD response values for each
participant were extracted for the significant clusters of the
ANCOVA analyses and post hoc t-tests (correcting for multi-
ple comparisons using least significant difference (LSD))
were conducted to identify the direction of the group
differences.
ANCOVAwithin-patient interaction effects
A 2×2 ANCOVA (2 medication conditions, 2 groups) with
rotational and translationmovement as covariate was conduct-
ed using randomised-based testing for voxel or cluster-wise
differences as described elsewhere (Bullmore et al. 2001).
Less than one false positive activation cluster was expected
at p<0.05 at voxel and p<0.01 at cluster level. For our a priori
hypothesised region in right IFC, a more lenient p<0.05 was
used as well as a region of interest analysis using the IFC as a
mask. Statistical measures of BOLD response for each partic-
ipant were then extracted in each of the significant clusters and
post hoc t tests (corrected for multiple comparisons with LSD)




ANOVAs showed no significant group differences in age (F
(df=2,61)=3; n.s.) but in IQ (F (df=2,61)=10, p<0.001)
which was significantly lower in ADHD relative to control
and ASD boys (p<0.005), who did not differ. Given that
ADHD children have typically lower IQ than their healthy
peers (Bridgett and Walker 2006), data were not covaried for
IQ, as covarying for a measure that is associated with the
condition would violate ANCOVA assumptions (Dennis
et al. 2009). Nonetheless, to assess the potential impact of
IQ, analyses were repeated with IQ as covariate. For group
differences in clinical measures, see Table 1.
Performance data
As expected, all subjects achieved approximately 50 % prob-
ability of inhibition, suggesting the algorithm was successful
and there were no differences between controls and patient
groups in this measure for either placebo (F (df=2,61)=1.2;
p=n.s.) nor fluoxetine (F (df=2,61)=2.7, p=n.s.) nor were
there any group or group by medication interaction effects for
the within-patients analysis (F (df=2,61)<1, p=n.s.).
MANOVA showed a trend for a significant group effect for
placebo (F (df=8,114); p<0.08), which was due to increased
omission errors between controls and patients under placebo
(F (df=2,61)=4, p<0.02). Post hoc analyses (corrected for
multiple testing using least significance difference (LDS))
showed that this was due to ADHD boys having increased
omission errors than both control (p<0.05) and ASD boys
(p<0.01) (Table 2). MANOVA for fluoxetine showed no
significant group effect (F (df=2,61)=1.2, p=n.s.).
Within the patient groups there were no significant group
(df=1,35) or group by medication interaction effects (df=1,
35) for any variables (F<1 for all measures).
Given that ADHD patients performed the task twice, but
controls only once, we also measured practice effects in the
ADHD group using repeated measures t tests between perfor-
mance measures at scans 1 and 2. No significant differences
were found (F (df=1,17)=0.02, p=n.s.).
FMRI data
Movement
The Euclidean formula described belowwas used to produce a
3-D movement value known as d which is representative of
movement in x, y and z. The formula was used to produce a d




p1−q1ð Þ2 þ p2−q2ð Þ2 þ p3−q3ð Þ2:
q
Repeated measures ANOVAs showed no significant group
by movement interaction effects in the Euclidean measures of
maximum xyz rotation (F (df=4118)=2, p=0.14) or maxi-
mum xyz translation (F(df=4118)=1, p=0.58). Nevertheless,
to eliminate any potential effects of non-significant variance in
motion, these Euclidean motion parameters for maximum xyz
translation and rotation were used as covariates in the fMRI
analyses.
Within-group activations are reported in the supplementary
results section and in supplementary Figs. S2 and S3.
Between-group differences between controls and patients
under placebo
ANCOVA between controls and patients on placebo showed
significant group differences in left middle/IFC, left OFC/
superior temporal lobe (STL) reaching into putamen and
globus pallidus and in left inferior parietal lobe (IPL). The
hypothesised difference in right IFC was observed at a more
lenient p<0.05 (Fig. 1a, Table 3) and confirmed by a region of
interest analysis (Talairach coordinates (x;y;z)=54;7;26; BA
45; 10 voxels).
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Post hoc analyses showed that the group effect in right IFC
was due to significantly increased activation in ASD relative
to control boys (p<0.005) and trend-wise compared to ADHD
boys (p<0.08). In left middle/IFC, ASD patients had
Table 2 Performance measures for the stop task for healthy controls, ADHD and ASD groups
Performance measure Controls ADHD placebo ADHD fluoxetine ASD placebo ASD fluoxetine
Mean SD Mean SD Mean SD Mean SD Mean SD
SSRT 161 107 132 81 142 109 140 125 142 103
PI 51 3 50 3 49 4 50 3 49 4
SSD 462 23 497 27 490 30 479 27 480 29
MRT to go trials 623 104 629 86 632 109 618 102 622 113
SD for MRT to go trials 174 39 194 44 194 60 168 39 166 43
Omission errorsa 5 5 9 8 9 9 3 5 3 3
PI percentage inhibition, SSRT stop signal reaction time, SSD average stop signal delay, MRT mean reaction time
SD = intrasubject variability of reaction time (in ms)
a ADHD > C, ASD
Fig. 1 Between-group brain
activation differences between
controls and patients under
placebo or fluoxetine for the
contrast of successful stop with
unsuccessful stop trials. a Axial
sections showing the between-
group ANCOVA comparison
findings between controls and
patients under placebo. Shown
underneath are the statistical
measures of BOLD response for
each of the three groups for each
of the brain regions that showed a
significant group effect. b Axial
sections for the between-group
ANCOVA comparison between
controls and patients under
fluoxetine. Talairach z
coordinates are indicated for slice
distance (in mm) from the
intercommissural line. The right
side of the image corresponds to
the right side of the brain
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significantly increased activation compared to both control
and ADHD boys (p<0.005) who activated this region during
failed inhibition and had a trend-wise reduction relative to
controls (p<0.08). In left OFC/STL/basal ganglia both control
and ASD boys, who did not differ from each other, showed
increased activation relative to ADHD boys who activated this
area during failed inhibition (p<0.005). Left IPL was signif-
icantly reduced in both patient groups relative to controls
(p<0.05), with ASD patients activating this area significantly
more during failed inhibition than ADHD (p<0.05).
To test whether group effects were related to task perfor-
mance, we correlated all clusters with SSRT and omission
errors, since they were lower in ADHD relative to controls
and ASD. The (reduced) activation in left OFC/basal ganglia
in ADHD was significantly negatively correlated with omis-
sion errors (r=−0.5, p<0.05). No other correlations were
significant.
Between-group differences between controls and patients
under fluoxetine
There were significant group differences in bilateral pre-
SMA/superior frontal cortex, SMA proper, left IPL/middle
temporal lobe, right IPL and precuneus (Fig. 1b, Table 3).
Post hoc analyses showed that control and ASD boys, who did
not differ, activated pre-SMA/superior frontal cortex signifi-
cantly more during successful inhibition than ADHD boys
who activated this cluster more during failed inhibition
(p<0.0001). SMA proper was significantly more activated in
patients, who did not differ relative to controls, who activated
this region more during failed inhibition (p<0.05). In bilateral
IPL, controls and ASD boys had increased activation during
successful inhibition relative to ADHD boys who activated
this region more during failed inhibition (p<0.05). In right
IPL, ASD boys also had increased activation relative to
controls (p<0.05). In precuneus, ADHD boys showed signif-
icantly enhanced activation for successful inhibition relative
to both ASD (p<0.05) and controls who activated this region
during failed inhibition and differed relative to ASD (p<0.05).
Correlations with behaviour showed that activation in pre-
SMA/superior frontal cortex during successful inhibition
was negatively correlated with SSRT in the ASD group
(r=−0.532, p<0.05). Activation in precuneus was negatively
correlated with SSRT in the ADHD group (r=−0.493,
p<0.05).
Effect size comparisons of case-control conditions to test
for significant “normalisation” effects
To establish whether the group differences between controls
and patients under each drug condition (ADHD/ASD under
placebo versus controls; ADHD/ASD under fluoxetine versus
controls) were significantly different, we directly compared
the effect sizes (ES) of the group differences from the two
case-control comparisons (Matthews and Altman 1996).
When comparing two effect sizes, the z test can evaluate
the likelihood of whether they are significantly heterogeneous.
The difference between the two effect sizes can be considered
a normalized variable, where the standard error of the differ-
ence is a combination of the standard errors of the two com-
parisons. Based upon this, the probability of a type I error can
be calculated using the formula: p (α)=(es1−es2)/sqrt(se12+
se2
2).
For the abnormalities in the ADHD patients, the effect sizes
of the ADHD placebo-control contrast was not significantly
different from the effect sizes of the ADHD fluoxetine-control
comparison for left OFC (z=−0.9, p=n.s.), right IFC (z=−0.6;
p=n.s.) or the left inferior parietal activation clusters (z=0.53,
p=n.s.), suggesting that the normalisation effects in these
clusters were not statistically significant.
Table 3 Brain activation differences between controls and patients on placebo or fluoxetine
Post hoc group differences Brain regions of activation differences Brodmann area (BA) Peak Talairach
coordinates (x;y;z)
Voxels Cluster p value
Placebo
C < ASD R inferior frontal cortex 44 54;15;26 16 0.03
C, ADHD < ASD L inferior/middle frontal cortex 44/45/46/9 −40;30;23 82 0.002
C, ASD > ADHD L STL/OFC/putamen/globus pallidus 38/47/11/25 −29;11;−26 73 0.008
C > ADHD > ASD L inferior parietal lobe 40 −29;−22;40 97 0.002
Fluoxetine
C, ASD > ADHD L + R pre-SMA/premotor/superior frontal cortex 6/8 −11;4;63 203 0.0006
C < ADHD, ASD SMA proper 6/8/9 −4;−11;50 42 0.007
ADHD < C < ASD R inferior parietal lobe/angular gyrus 6 36;−63;30 50 0.004
C, ASD > ADHD L inferior parietal lobe/middle temporal 40/39 −47;−63;26 188 0.0002
C < ASD < ADHD Precuneus 40/39 7;−67;43 114 0.002
STL superior temporal lobe, OFC Orbitofrontal cortex, SMA supplementary motor area
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For the abnormalities in the ASD patients, however, the
effect sizes for the ASD placebo-control contrast were signif-
icantly different from the effect sizes for the ASD fluoxetine-
control contrast for left IFC (z=2.8, p<0.005) and right IFC
(z=−2.5, p<0.01), both of which were enhanced under place-
bo but normalised under fluoxetine, and for left inferior pari-
etal lobe, which was significantly reduced in ASD relative to
controls under placebo, but enhanced under fluoxetine (z=2.3,
p<0.02). The findings show that all normalisation effects in
these clusters were statistically significant.
Control for IQ
To assess the potential impact of IQ on case-control group
differences, all analyses were repeated with IQ as a covariate.
All clusters remained at a p<0.01, apart from left OFC in the
placebo between-group ANCOVA and right IPL in the fluox-
etine between-group ANCOVA, which survived at a more
lenient p<0.05.
Within-patients group by medication interaction effects
ANCOVA analysis with group as dependent variable and drug
as within-group variable showed a significant group by med-
ication interaction effect in five clusters. (1) Fluoxetine re-
duced pre-SMA activation in ADHD boys, whereas it in-
creased it in ASD boys during successful inhibition
(p<0.005). (2) Fluoxetine increased activation in left OFC/
STL/putamen/globus pallidus in ADHD during successful
inhibition relative to placebo, but reduced it in ASD
(p<0.05). (3) Both patient groups activated left IPL during
failed inhibition under placebo, but ADHD boys activated this
region more during failed inhibition and ASD boys more
during successful inhibition under fluoxetine (p<0.0001).
(4) Right cerebellum activation was increased under fluoxe-
tine in ADHD relative to placebo for successful inhibition,
while ASD boys activated this area during failed inhibition
under both placebo and fluoxetine (p<0.05). (5) At a more
lenient p<0.05, relative to placebo, fluoxetine increased acti-
vation in the hypothesised right IFC during successful inhibi-
tion in ADHD and decreased it in ASD (p<0.05) (Fig. 2,
Table 4). The same cluster was also confirmed by a region-of-
interest analysis (Talairach coordinates (x;y;z)=51;4;30; BA
45; 7 voxels).
No significant correlations with performance were ob-
served. All findings remained when IQ was covaried for.
Discussion
The findings reveal opposite brain dysfunction patterns in
inhibitory brain regions in ADHD and ASD as well as
opposite disorder-dissociated modulation effects of fluoxetine
on these neurofunctional abnormalities. Relative to controls,
ADHD patients showed reduced left OFC/basal ganglia acti-
vation, whereas ASD patients showed enhanced bilateral ven-
trolateral prefrontal activation relative to ADHD and controls.
Fluoxetine normalized these disorder-dissociated brain abnor-
malities relative to controls, via disorder-dissociated opposite
effects within patients: fluoxetine enhanced the abnormally
reduced OFC/basal ganglia activation in ADHD, but reduced
it in ASD. In contrast, it reduced the abnormally enhanced IFC
activation in ASD, but enhanced it in ADHD. However,
rigorous testing for the significance of these normalisation
effects showed that these were only significant for the abnor-
mality clusters in ASD. Furthermore, fluoxetine also had
opposite disorder-dissociated effects on other inhibition areas
such as pre-SMA and cerebellum: these were, respectively,
enhanced (SMA) and reduced (cerebellum) in ADHD with
fluoxetine relative to placebo, but reduced (SMA) and en-
hanced (cerebellum) in ASD.
The finding of disorder-specific increased activation in
ASD relative to controls and ADHD in the left and right
(trend-wise significant relative to ADHD) IFC extends our
previous finding of increased left IFC activation in young
adults with Asperger's syndrome during a go/no-go task
(Schmitz et al. 2006) by demonstrating disorder-specificity
relative to ADHD. Predominantly, the right (Chambers et al.
2009; Rubia et al. 2003) but also left IFC (Hampshire et al.
2010; Rubia et al. 2011; Rubia et al. 2001; Rubia et al. 2007)
are crucial areas mediating response inhibition and ASD pa-
tients may have needed to recruit these areas more for com-
parable task performance. ADHD patients had no
underactivation in these areas relative to controls, unlike ob-
served previously (Cubillo et al. 2014; Hart et al. 2013; Rubia
2011; Rubia et al. 1999; Rubia et al. 2005b), but relative to
ASD. This, and the lack of a significant difference between
controls and ADHD boys in SSRT may be due to long-term
effects of stimulant medication, which has been associated
with more normal prefrontal and striatal function (Hart et al.
2012; Hart et al. 2013; Rubia et al. 2014), as 11 of the ADHD
boys were on chronic methylphenidate medication, even if
taken off medication prior to the scan. It is also interesting to
note that the enhanced omission errors which were observed
in ADHD patients relative to both control and ASD boys
under placebo were correlated with reduced IFC-striatal acti-
vation under placebo. It has been suggested that omission
errors are indicative of an alternative strategy that ADHD
boys may employ to decrease their number of failed inhibi-
tions (Tannock et al. 1989). Therefore, although there was no
behavioural evidence for poor inhibitory performance using
the inhibitory measure of the SSRT, there were significant
behavioural differences in omission errors in ADHD patients
under placebo. The differences correlated with the
neurofunctional deficits and were no longer observed under
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fluoxetine. The disorder-exclusive deficits in ADHD adoles-
cents in the left OFC/basal ganglia relative to controls extend
prior findings of OFC-striatal deficits in ADHD (Cubillo et al.
2014; Hart et al. 2013; Rubia 2011; Rubia et al. 1999; Rubia
et al. 2005b; Rubia et al. 2014). Our results therefore show
disorder-dissociated frontal lobe dysfunctions in ADHD and
ASD boys during inhibition relative to controls: with ASD
patients showing significantly enhanced bilateral IFC activa-
tion and ADHD boys showing significantly reduced OFC/
basal ganglia activation, which furthermore correlated with
their enhanced omission errors during task performance.
Fluoxetine normalized all disorder-dissociated frontal brain
dysfunctions due to opposite modulation effects in both dis-
orders, which were, however, only significant in the ASD
group. Fluoxetine significantly reduced bilateral OFC activa-
tion in the ASD group but enhanced it in ADHD. Under
fluoxetine, ADHD patients also no longer showed enhanced
omission errors, which were reduced under placebo and cor-
related with the OFC deficits. Fluoxetine also had an opposite
up/downregulation effect on another key inhibition region, the
pre-SMA: this was upregulated in ASD and hence increased
relative to controls and ADHD, but downregulated in ADHD
and hence reduced relative to controls and ASD. The upreg-
ulation effect of fluoxetine on right IFC and left OFC-striatal
regions in ADHD extends prior evidence on SE agonist mod-
ulation of these areas in healthy adults during inhibitory
control (Del-Ben et al. 2005) to the ADHD population. Most
intriguing, however, are the consistently opposite reduction
effects of fluoxetine on these frontal activations in the ASD
group. Opposite activation effects could possibly reflect group
differences in baseline SE levels, as evidenced by lower
platelet SE levels in ADHD children compared to controls
(Spivak et al. 1999), and increased baseline platelet, blood and
prefrontal SE levels in 30 % of individuals with ASD relative
to controls (Hranilovic et al. 2007; Mulder et al. 2004;
Nakamura et al. 2010; Piven et al. 1991). In addition, ASD
patients have abnormal 5-HT synthesis (Chugani et al. 1997),
5-HT transporter (Makkonen et al. 2008; Nakamura et al.
2010) and 5-HT2A receptor binding (Murphy et al. 2006).
Therefore, fluoxetine may increase the low SE baseline of
children with ADHD to normal levels, leading to normalized
activation in fronto-striatal areas. Whereas in children with
ASD, the increase in SE in an already hyperserotonemic
system may activate a negative feedback mechanism via
Table 4 Group by drug interaction effects within ADHD and ASD patients
Brain regions of activation Brodmann area (BA) Peak Talairach coordinates (x;y;z) Voxels Cluster p value
R inferior/middle frontal cortex 44/9 51;0;26 21 0.03
R pre-SMA/premotor/superior frontal cortex 6/8 −7:33;56 1085 0.0003
L STL/OFC/putamen/globus pallidus 38/47/11/25 −4;−7;−26 452 0.004
L inferior parietal/middle/STL/occipital lobe 39/40/22/19 −43;−67;30 237 0.008
R cerebellum 22;−41;−17 139 0.0005
STL superior temporal lobe, OFC orbitofrontal cortex, SMA supplementary motor area
Fig. 2 Within-patient group by
medication interaction effects.
Axial sections showing within-
patient group by medication
interaction effects for the contrast
of successful stop-unsuccessful
stop trials. Shown underneath are
the statistical measures of BOLD
response for each of the brain
regions that showed a significant
group by medication interaction
effect within patients. Talairach z
coordinates are indicated for slice
distance (in mm) from the
intercommissural line. The right
side of the image corresponds to
the right side of the brain
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activation of 5-HT1A autoreceptors (Sibley et al. 2007), lead-
ing to a decrease in SE and in fronto-striatal activation.
Despite significant modulation effects on brain activation,
fluoxetine had no effect on inhibitory performance. However,
the enhanced omission errors that were observed in ADHD
patients under placebo relative to controls were no longer
significant under fluoxetine. Furthermore, it is well document-
ed that brain function is more sensitive to pharmacological
manipulations than inhibitory performance (Cubillo et al.
2014; Rubia et al. 2011; Rubia et al. 2005a). In addition, one
of the upregulated regions in ASD in a key inhibitory area, the
pre-SMA, was correlated with SSRT, suggesting a relation-
ship between activation changes and inhibitory performance.
The strengths of this study are carefully selected and non-
comorbid patient groups who had no psychiatric comorbidi-
ties and, in the case of the ASD group, were medication-naïve.
A limitation of this study is that for ethical and financial
reasons, the control group was scanned only once, while
patients were scanned twice which could have accounted for
the lack of performance differences. The significantly lower
IQ in the ADHD compared to the other two groups is another
limitation. However, covariance analysis showed that the
findings were not affected by IQ. Furthermore, stop task
performance has been shown to be independent of IQ
(Friedman et al. 2006). Lastly, while the contrast of successful
and unsuccessful stop trials controls for the attentional oddball
effect of the low frequency of stop stimuli, it may be over-
conservative, as during unsuccessful stop trials subjects may
also attempt, but not achieve to inhibit.
Conclusions
To summarise, ADHD and ASD patients showed opposite
brain activation abnormalities relative to controls: ADHD boys
showed reduced while ASD boys enhanced frontal activation.
Importantly, fluoxetine had a disorder-dissociated opposite
effect on frontal brain dysfunctions, enhancing frontal activa-
tion in ADHD and reducing it in ASD which could suggest
differential underlying SE baseline levels in the two disorders.
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